NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  3D Systems Corporation (“3D Systems” or the “Company”) (NYSE: DDD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether 3D Systems and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On M ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Adverum Biotechnologies, Inc. following the company's announcement of the need to restate its financial statements due to accounting errors [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Adverum and is looking into claims of securities fraud or other unlawful practices by the company and its officers/directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2]. Group 2: Financial Disclosure - On March 31, 2025, Adverum disclosed that certain previously issued financial statements should no longer be relied upon due to non-cash errors related to tenant improvement allowances for an operating lease in North Carolina [3]. - The company announced it will restate its financial statements for the years ended December 31, 2022, and 2023, as well as for the quarterly periods in 2023 and 2024 [3]. - Following this announcement, Adverum's stock price dropped by $0.54, or 12.36%, closing at $3.83 per share on April 1, 2025 [3].

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  TechTarget, Inc. (“TechTarget” or the “Company”) (NASDAQ: TTGT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether TechTarget and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Apri ...

Core Viewpoint - A lawsuit has been filed against Ready Capital Corporation and its senior executives for potential violations of federal securities laws, focusing on misrepresentation of the company's financial health due to non-performing loans in its commercial real estate portfolio [1][2][4]. Group 1: Company Overview - Ready Capital is a real estate finance company that originates, acquires, finances, and services lower-to-middle-market commercial real estate loans, small business administration loans, and other real estate-related investments [3]. Group 2: Legal Allegations - The lawsuit alleges that the defendants misrepresented the severe impact of significant non-performing loans on Ready Capital's business, which were not accurately reflected in the company's expected credit loss or valuation allowances [4]. - The complaint is filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Ready Capital stock [2]. Group 3: Financial Impact - On March 3, 2025, Ready Capital announced a financial charge of $382 million, including $284 million related to non-performing loans, and a reduction in its dividend to $0.125 per share [5]. - Following this announcement, Ready Capital's stock price fell nearly 27%, from $6.93 per share on February 28, 2025, to $5.07 per share on March 3, 2025 [6].

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BigBear.ai Holdings, Inc. (NYSE: BBAI) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in BigBear.ai, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bigbearai-holdings-inc. Investors have until June 10, 2025, to ask the Court to be ...

Core Viewpoint - A lawsuit has been filed against The Bancorp, Inc. and its senior executives for potential violations of federal securities laws, specifically regarding misrepresentation of risks associated with its loan portfolio [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Delaware, captioned Linden v. The Bancorp, Inc., et al., No. 25-cv-00326, with investors having until May 16, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased Bancorp stock [2]. Group 2: Company Background - Bancorp is a financial holding company involved in institutional banking, commercial real estate bridge lending, small business lending, and commercial fleet leasing, with its REBL loans primarily collateralized by apartment buildings [3]. Group 3: Allegations of Misrepresentation - The complaint claims that Bancorp misrepresented the risks of default or loss on its REBL loan portfolio and that its credit loss methodology was inadequate [4]. - It is alleged that Bancorp's internal controls over financial reporting contained at least one material weakness [4]. Group 4: Stock Performance and Impact - Following a report from Culper Research on March 21, 2024, which highlighted the risks associated with Bancorp's REBL loans, the stock price fell over 10%, from $36.04 to $32.12 [5]. - On October 24, 2024, Bancorp reported a net income of $51.5 million, leading to a 14% decline in stock price from $54.96 to $47.01 due to increased credit losses [6]. - On March 4, 2025, Bancorp disclosed issues with its Annual Report for the fiscal year ended December 31, 2024, causing a 4.4% drop in stock price from $53.59 to $51.25 [7].

Group 1 - RH is under investigation for potential violations of federal securities laws, as announced by Bleichmar Fonti & Auld LLP [1] - RH operates primarily in the home furnishings market, offering a variety of products including furniture, lighting, textiles, and outdoor furnishings [2] - Despite claims of accelerated demand, RH was actually facing softening demand and macroeconomic challenges that necessitated delays in new collections [3] Group 2 - On April 2, 2025, RH reported disappointing earnings for FY 2024, citing softening demand and excess inventory valued between $200 million to $300 million [4] - Following the earnings report, RH's stock price plummeted by 40%, dropping from $249.35 to $149.39 per share within a day [4]

NEW YORK, April 28, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Avis Budget Group, Inc. (NASDAQ: CAR) between February 16, 2024 and February 10, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 24, 2025. Attorney Advertising. Prior results do not guarantee a similar ...

Core Viewpoint - ICU Medical, Inc. is under investigation for potential securities fraud and unlawful business practices following a warning from the FDA regarding unauthorized changes to its infusion pump products [1][2]. Group 1: FDA Warning and Product Issues - On April 22, 2025, ICU disclosed that it received a warning letter from the FDA, which cited unauthorized modifications to two of its infusion pump products [2]. - The FDA's letter described the pumps as "adulterated" and "misbranded," indicating that the changes could significantly affect the functionality of the devices, particularly their delivery profile and alarm functionality [2]. - Concerns were raised about the safety and efficacy of the devices due to these modifications, questioning the adequacy of ICU's regulatory disclosures [2]. Group 2: Stock Market Reaction - Following the FDA warning, ICU's stock price dropped by $6.04 per share, or 4.42%, closing at $130.68 per share on April 22, 2025 [3]. Group 3: Legal Investigation - Pomerantz LLP is investigating claims on behalf of ICU investors regarding potential securities fraud or other unlawful business practices by the company and its officers or directors [1].

Core Viewpoint - Northrop Grumman Corporation is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q1 2025, which included significant charges related to its B-21 bomber program [1][2]. Financial Performance - Northrop Grumman reported revenue of $9.47 billion for Q1 2025, reflecting a 7% year-over-year decline and falling short of consensus estimates by $480 million [2]. - The company incurred a pretax charge of $477 million associated with manufacturing updates for the B-21 bomber program, attributed to inflationary factors by the CEO [2]. Stock Market Reaction - Following the announcement of the financial results, Northrop Grumman's stock price dropped by $67.25 per share, or 12.66%, closing at $464.08 per share on April 22, 2025 [2].